Science Explorer Back to mapMap
Discussion
Topic · Molecular Biology

Cancer therapeutics and mechanisms

Cancer therapeutics and mechanisms is a research topic within Molecular Biology. Science Explorer counts 35k research works in it since 1950. 10.1% of them reached the world's top 10% most cited for their field and year.

This cluster of papers focuses on the structure, function, inhibition, and genetic variants of DNA topoisomerases, particularly their roles in chemotherapy, the mechanism of action of specific inhibitors such as irinotecan and quinolones, and their impact on genomic stability. The papers also explore the potential use of genetic variants in predicting drug toxicity and treatment outcomes.

  • Topoisomerases
  • DNA
  • Inhibitors
  • Chemotherapy
  • Genetic Variants
  • Irinotecan
  • Quinolones
  • Anticancer Drugs
  • Enzyme Mechanism
  • Genomic Stability
Research works
35k
fractional, since 1950
In the world top 10%
3.5k
per year above
Top-10% rate
10.1%
share of its works in the world top 10%
Growth, 2018-21 → 2022-25
-3%
the tick is no change
Largest producer
China
30% of the 10 largest, 2022-now
Cancer therapeutics and mechanisms

Which countries lead Cancer therapeutics and mechanisms research?

By volume, China and the United States publish the most (877 and 730 works in 2022-now).

By volume, 2022-now

  1. 1 China 877 works
  2. 2 United States 730 works
  3. 3 India 534 works
  4. 4 Egypt 139 works
  5. 5 Japan 139 works
  6. 6 United Kingdom 104 works
  7. 7 Italy 103 works
  8. 8 Germany 102 works
  9. 9 Russia 101 works
  10. 10 Saudi Arabia 97 works

How concentrated that is

The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.

China: 30.0%United States: 24.9%India: 18.3%Egypt: 4.8%6 others listed: 22.1%30%largest
China877 · 30.0%United States730 · 24.9%India534 · 18.3%Egypt139 · 4.8%6 others listed646 · 22.1%

Shares of the rows listed above, not of the whole node.

Which institutions lead Cancer therapeutics and mechanisms research?

By volume in 2022-now, Russian Academy of Sciences publishes the most Cancer therapeutics and mechanisms research, followed by National Institutes of Health and Chinese Academy of Sciences.

By volume, 2022-now

  1. 1 Russian Academy of SciencesRussia 39 works
  2. 2 National Institutes of HealthUnited States 36 works
  3. 3 Chinese Academy of SciencesChina 31 works
  4. 4 Centre National de la Recherche ScientifiqueFrance 26 works
  5. 5 Sun Yat-sen UniversityChina 24 works
  6. 6 Harvard UniversityUnited States 22 works
  7. 7 King Saud UniversitySaudi Arabia 22 works
  8. 8 Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina 22 works
  9. 9 Sichuan UniversityChina 21 works
  10. 10 Council of Scientific and Industrial ResearchIndia 20 works

Who are the leading researchers in Cancer therapeutics and mechanisms?

The most-cited researchers publishing on Cancer therapeutics and mechanisms include Eric S. Lander, George Davey Smith and Guido Kroemer.

  1. 1 Eric S. Lander United States 524k citations
  2. 2 George Davey Smith United Kingdom 435k citations
  3. 3 Guido Kroemer France 386k citations
  4. 4 Gad A. Getz United States 364k citations
  5. 5 Jun Wang China 340k citations
  6. 6 Róbert Langer United States 303k citations
  7. 7 Robert A. Weinberg United States 301k citations
  8. 8 Ulrich K. Laemmli Switzerland 285k citations
  9. 9 Todd R. Golub United States 283k citations
  10. 10 Matthew M. Meyerson United States 280k citations

Ranked by citations received across their whole record, among researchers with at least three works on this topic.

What are the most cited papers in Cancer therapeutics and mechanisms?

The most cited paper in Cancer therapeutics and mechanisms is "Cisplatin in cancer therapy: Molecular mechanisms of action" (Shaloam R. Dasari, Paul Bernard Tchounwou, 2014), with 5,600 citations. Next come "Multidrug resistance in cancer: role of ATP–dependent transporters" (5,578) and "Cancer drug resistance: an evolving paradigm" (4,739).

Most cited papers
#PaperReleasedCitations
1 Cisplatin in cancer therapy: Molecular mechanisms of action Shaloam R. Dasari, Paul Bernard Tchounwou · European Journal of Pharmacology Open access 21 Jul 2014 5,600
2 Multidrug resistance in cancer: role of ATP–dependent transporters Michael M. Gottesman, Tito Fojo, Susan E. Bates · Nature reviews. Cancer Review 2002 5,578
3 Cancer drug resistance: an evolving paradigm Caitriona Holohan, Sandra Van Schaeybroeck, Daniel B. Longley et al. · Nature reviews. Cancer Review 24 Sep 2013 4,739
4 EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib Susumu S. Kobayashi, Titus J. Boggon, Tajhal Dayaram et al. · New England Journal of Medicine Open access 23 Feb 2005 3,981
5 Targeting multidrug resistance in cancer Gergely Szakács, Jill K. Paterson, Joseph Aloysius Ludwig et al. · Nature Reviews Drug Discovery Review Mar 2006 3,674
All 100 most cited papers, with filters and sorting

Where is Cancer therapeutics and mechanisms research done?

The largest centres of Cancer therapeutics and mechanisms research in 2022-now are Beijing (China), Shanghai (China), Guangzhou (China) and Moscow (Russia). Among places with at least 20 works in it, it is an unusually large share of all research in Bethesda, Cairo and Giza.

Largest cities, 2022-now

  1. 1 BeijingChina 106 works
  2. 2 ShanghaiChina 70 works
  3. 3 GuangzhouChina 60 works
  4. 4 MoscowRussia 48 works
  5. 5 CairoEgypt 47 works
  6. 6 New YorkUnited States 43 works
  7. 7 RiyadhSaudi Arabia 40 works
  8. 8 HangzhouChina 39 works
  9. 9 SeoulSouth Korea 39 works
  10. 10 NanjingChina 36 works

Where it is the local speciality

  1. BethesdaUS · 31.1 works6.5×
  2. CairoEG · 47.5 works5.0×
  3. GizaEG · 27.6 works4.8×
← less than its size predicts1×more →

Location quotient: how much more of its research is in Cancer therapeutics and mechanisms than the world average.

See Cancer therapeutics and mechanisms on the map

Where is the best place to study Cancer therapeutics and mechanisms?

Among universities, judged by research, Al-Azhar University, Harvard University and King Saud University score highest, combining citation excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.

0%10%20%30%mean 15.64%fractional works in this field (log) →share of work in the world top 10% →Al-Azhar UniversityHarvard UniversityCairo UniversityKing Saud University
above the meannear itbelow it

One dot per university in the first ten of the table below, at the default weights. The upper left is the interesting corner: small places doing unusually strong work.

Citation excellenceshare of its work in the world top 10%, 2022-now and all time averaged
40%
Specialisationhow much of its work is in this field, counted up to 10× the world share
10%
Sizeits output in this field, on a log scale
30%
Growthoutput growth, counted from -20% to +20%
10%
Internationalshare of its work with a co-author abroad
10%
Each slider sets a weight; the share it gets of the score is beside it.
#UniversityScoreTop 10%SpecialisationWorksGrowth
1Al-Azhar UniversityEgypt 77.226.7%10.5×14 +2.9%
2Harvard UniversityUnited States 74.022.8%1.9×22 -33.5%
3King Saud UniversitySaudi Arabia 69.311.6%6.3×22 +67.5%
4Cairo UniversityEgypt 64.221.0%5.7×15 +75.7%
5Sichuan UniversityChina 58.916.9%2.6×21 +25.0%
6Sun Yat-sen UniversityChina 53.810.6%3.2×24 -2.4%
7Vanderbilt UniversityUnited States 49.212.0%4.9×12 +3.0%
8Mansoura UniversityEgypt 49.016.9%6.4×10 +58.7%
9Academy of Scientific and Innovative ResearchIndia 46.29.0%11.8×13 +105.0%
10Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina 44.88.9%5.8×22 -19.0%

Universities only. The score blends citation excellence (40%), size (30%), specialisation (10%), growth (10%), international reach (10%), 2022-now; growth compares 2018-21 with 2022-25 and counts up to +20%, since a jump from a small base is mostly noise.

Every institution in Cancer therapeutics and mechanisms, country by country

Is Cancer therapeutics and mechanisms research growing?

Output in 2022-2025 was 3% lower than in 2018-2021, peaking in 2022.

still counting19801990200020102020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Cancer therapeutics and mechanisms as a percentage of every work published that year, 0.018% in 2024.

still counting0.025%0.050%0.075%Cancer therapeutics and mechanisms0.015% in 202519801990200020102020

Fractional works of Cancer therapeutics and mechanisms over all fractional works that year. How the balance of science has shifted.

How much of it reaches the world top 10%

Year by year.

still counting5%10%15%Cancer therapeutics and mechanisms10.4% in 2025200020102020

Of each year's works in it, the share that reached the world's 10% most cited for their field and year. A field is the world for its own topics, so there is no other line to hold it against.

Which topics inside it are moving

Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.

Discussion

Ask a question or share a note about Cancer therapeutics and mechanisms. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.